FDA Panel Issues Mixed Review of Obesity Drug

Food and Drug Administration reviewers issued a decidedly mixed analysis of the obesity drug Lorqess, finding some modest effectiveness in lowering weight during recent research but safety data that may not be robust enough.
The Wall Street Journal